259 related articles for article (PubMed ID: 34239773)
1. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.
Van Wigcheren GF; De Haas N; Mulder TA; Horrevorts SK; Bloemendal M; Hins-Debree S; Mao Y; Kiessling R; van Herpen CML; Flórez-Grau G; Hato SV; De Vries IJM
Oncoimmunology; 2021; 10(1):1935557. PubMed ID: 34239773
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
[TBL] [Abstract][Full Text] [Related]
3. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
4. Expansion of Monocytic Myeloid-Derived Suppressor Cells in Patients Under Hemodialysis Might Lead to Cardiovascular and Cerebrovascular Events.
Xing YF; Cai JR; Qin JJ; Zhou WY; Li CM; Li X
Front Immunol; 2020; 11():577253. PubMed ID: 33584644
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways.
van Wigcheren GF; Cuenca-Escalona J; Stelloo S; Brake J; Peeters E; Horrevorts SK; Frölich S; Ramos-Tomillero I; Wesseling-Rozendaal Y; van Herpen CML; van de Stolpe A; Vermeulen M; de Vries IJM; Figdor CG; Flórez-Grau G
J Biol Chem; 2023 Nov; 299(11):105276. PubMed ID: 37739035
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
7. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
Bitsch R; Kurzay A; Özbay Kurt F; De La Torre C; Lasser S; Lepper A; Siebenmorgen A; Müller V; Altevogt P; Utikal J; Umansky V
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35301236
[TBL] [Abstract][Full Text] [Related]
8. Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis.
Liu YF; Zhuang KH; Chen B; Li PW; Zhou X; Jiang H; Zhong LM; Liu FB
Arthritis Res Ther; 2018 Aug; 20(1):168. PubMed ID: 30075733
[TBL] [Abstract][Full Text] [Related]
9. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
[TBL] [Abstract][Full Text] [Related]
10. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
[TBL] [Abstract][Full Text] [Related]
12. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients.
Utrero-Rico A; Laguna-Goya R; Cano-Romero F; Chivite-Lacaba M; Gonzalez-Cuadrado C; Rodríguez-Sánchez E; Ruiz-Hurtado G; Serrano A; Fernández-Ruiz M; Justo I; González E; Andrés A; Paz-Artal E
Transplantation; 2020 Dec; 104(12):2599-2608. PubMed ID: 32068661
[TBL] [Abstract][Full Text] [Related]
13. The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.
Bayik D; Lee J; Lathia JD
Exp Suppl; 2022; 113():189-217. PubMed ID: 35165865
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.
Kim NR; Kim YJ
Cancer Med; 2019 Jan; 8(1):276-288. PubMed ID: 30592157
[TBL] [Abstract][Full Text] [Related]
15. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
[TBL] [Abstract][Full Text] [Related]
16. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy.
Tomela K; Pietrzak B; Galus Ł; Mackiewicz J; Schmidt M; Mackiewicz AA; Kaczmarek M
Cells; 2023 Mar; 12(5):. PubMed ID: 36899926
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.
Shime H; Maruyama A; Yoshida S; Takeda Y; Matsumoto M; Seya T
Oncoimmunology; 2017; 7(1):e1373231. PubMed ID: 29296526
[TBL] [Abstract][Full Text] [Related]
19. TIE-2 Signaling Activation by Angiopoietin 2 On Myeloid-Derived Suppressor Cells Promotes Melanoma-Specific T-cell Inhibition.
Marguier A; Laheurte C; Lecoester B; Malfroy M; Boullerot L; Renaudin A; Seffar E; Kumar A; Nardin C; Aubin F; Adotevi O
Front Immunol; 2022; 13():932298. PubMed ID: 35935946
[TBL] [Abstract][Full Text] [Related]
20. Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.
Oliver L; Alvarez R; Diaz R; Valdés A; Colligan SH; Nemeth MJ; Twum DYF; Fernández A; Fernández-Medina O; Carlson LM; Yu H; Eng KH; Hensen ML; Rábade-Chediak ML; Fernández LE; Lee KP; Perez L; Muhitch JB; Mesa C; Abrams SI
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36150744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
